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1. Introduction
Several observations from human patients as well as 
inflammatory rodent models have proven that microbiome 
is a central driver of chronic gut inflammation (Hirata 
et al., 2016; Wehkamp and Frick, 2016). Perturbations 
of the commensal microbiota, termed dysbiosis, are 
commonly observed in gut diseases, where promote 
mucosal inflammation through an imbalance between 
the protective bacterial species and the most dangerous 
ones (Von Martels et al., 2017). This explains the increasing 
use of live bacteria (probiotics) as a useful strategy to 
manipulate the microbiome improving the dysbiosis in 
patients with intestinal inflammation (Grimm and Riedel, 
2016; Sánchez et al., 2016). Interestingly, probiotics have 
been recently used to reduce features associated with 
adherent invasive Escherichia coli (AIEC) bacteria that have 
been found greatly increased in patients with inflammatory 
bowel diseases (IBD) (Huebner et al., 2011; Rolhion and 
Darfeuille-Michaud, 2007).
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Abstract
Current research into original therapies to treat intestinal inflammation is focusing on no-drug therapies. KLD is 
a mixture of krill oil (KO), probiotic Lactobacillus reuteri (LR), and vitamin D (VitD3). The aim of this study was 
to assess in vitro and in vivo the potential cooperative effects of KLD in reducing gut inflammation. Colorectal 
adenocarcinoma cell lines, CACO2 and HT29, and C57BL/6 mice were used for in vitro and in vivo analyses, 
respectively. Cells were exposed to cytomix (interferon gamma + tumour necrosis factor alpha (TNF-α)) to induce 
inflammation or co-exposed to cytomix and KO, LR and VitD3 alone or to cytomix and KLD. Animals were treated 
for 7 days with dextran sodium sulphate (DSS) to induce colitis or with DSS and KLD. In vitro assays: F-actin 
expression was analysed by immunofluorescence; scratch test and trans-epithelial electric resistance test were 
performed to measure wound healing; adhesion/invasion assays of adhesive and invasive Escherichia coli (AIEC) 
bacteria were made; mRNA expression of TNF-α, interleukin (IL)-8 and vitamin D receptor (VDR) was detected by 
quantitative PCR. In vivo assays: body weight, clinical score, histological score and large intestine weight and length 
were estimated; mRNA expression of TNF-α, IL-1β, IL-6, IL-10 by quantitative PCR; VDR expression was detected 
by quantitative PCR and immunohistochemistry. In vitro: KLD restores epithelial cell-cell adhesion and mucosal 
healing during inflammation, while decreases the adhesiveness and invasiveness of AIEC bacteria and TNF-α and 
IL-8 mRNA expression and increases VDR expression. In vivo: KLD significantly improves body weight, clinical 
score, histological score and large intestine length of mice with DSS-induced colitis and reduces TNF-α, IL-1β 
and IL-6 mRNA levels, while increases IL-10 mRNA and VDR levels. KLD has significant effects on the intestinal 
mucosa, strongly decreasing inflammation, increasing epithelial restitution and reducing pathogenicity of harmful 
commensal bacteria.
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The composition of gut microbiota is deeply influenced 
by diet, one of the most influential lifestyle factors 
contributing to the rise of autoimmunity as well as 
inflammatory diseases, in both developed and developing 
countries (Albenberg and Wu, 2014; Dolan and Chang, 
2016). In particular, the spread of the ‘Western’ diet, high 
in fat and protein but low in fruits and vegetables, may 
be associated with the increase of many diseases, such 
as obesity, type 2 diabetes, IBD, and food allergies (Hou 
et al., 2011; Kumari and Kozyrskyj, 2017; Uranga et al., 
2016). The typical Western diet has a much greater ratio 
of n-6 polyunsaturated fatty acids (PUFAs), which display 
proinflammatory and immunoactive functions, compared 
with n-3 PUFAs, showing anti-inflammatory properties 
(Simopoulos, 2016; Wall et al., 2010). Recent evidence 
suggest that increasing the dietary intake of n-3 PUFAs 
(e.g. eicosapentaenoic acid (EPA) and docosahexaenoic 
acid (DHA)), through consumption of fatty fish or fish-oil 
supplements, may reduce the incidence of many chronic 
diseases that involve inflammatory processes (Jiang et al., 
2016).
A number of studies have also consistently revealed 
an association between vitamin D deficiency and the 
occurrence of intestinal malabsorption syndromes, 
including cystic fibrosis, celiac disease, short bowel 
syndrome and IBD while vitamin D supplementation has 
been associated with decreased colitis disease activity and/
or alleviated symptoms in patients (Margulies et al., 2015; 
White, 2016; Zhang et al., 2013).
Previously, we showed that the use of krill oil (KO), a 
marine derived oil rich in phospholipids, the antioxidant 
astaxanthin and omega-3 fatty acids, is able to decrease 
intestinal inflammation (Costanzo et al., 2016). Afterwards, 
we showed that the use of DHA plus vitamin D treatment 
improves features of non-alcoholic fatty liver disease in 
children with serum vitamin D deficiency (Della Corte et 
al., 2016).
In the present paper, we aim to assess in vitro and in vivo 
the potential cooperative effects of a mixture (KLD) of KO, 
the probiotic Lactobacillus reuteri (LR), and vitamin D in 
down-regulating gut inflammation by improving mucosal 
healing and epithelial barrier permeability as well as limiting 
pathogenicity of harmful intestinal bacteria.
2. Material and methods
KLD components
KO (Giellepi SPA, Milan, Italy), whose specific composition 
is phospholipids (51%, w/w), DHA (7%, w/w), EPA (12%, 
w/w), omega-3 (-3, or PUFA-3) (21%, w/w), astaxanthin 
(0.04%, w/w). The manufacturer supplied a certificate 
of analysis for the use in nutritional supplements and 
functional food, which includes total of active ingredients, 
physical and chemical tests and microbiological tests.
VitD3 (Giellepi SPA), whose specific name is 25-diidrossi-
vitamin D3(1,25(OH)2D3). The manufacturer supplied a 
certificate of analysis for the use in nutritional supplements 
and functional food, which includes total of active 
ingredients, physical and purity tests.
LR (BioGaia, Stockholm, Sweden) was cultured in De 
Man, Rogosa and Sharpe (MRS; Sigma-Aldrich, Buchs, 
Switzerland) agar plates for 24 h at 37 °C and then sub-
cultured in MRS Broth with overnight incubation at 
150 rpm, 37 °C. The manufacturer supplied a certificate 
of analysis for the use in nutritional supplements and 
functional food, which includes quality control tests and 
microbiological specifications.
KLD mixture used for in vitro experiments consists of: 
KO [0.25 mg/ml] + VitD3 [100nM] + LR [1×109 cfu/ml] 
in eukaryotic cell growth media (DMEM or McCoy’s 5A); 
for in vivo experiments concentrations were: KO [0.8 mg/
gr] + VitD3 [2.5×10-5 mg/gr] + LR [5×107 cfu/gr] pro die 
in phosphate buffered saline (PBS); 0.2 ml of KLD was 
administered by gavage twice daily.
This specific ratio and combination were chosen as follows: 
KO: according to the allometric scaling laws (West and 
Brown, 2005) and since DHA+EPA are 20% in KO, by 
administering 16 mg/mouse (0.8 mg/gr) pro die, the 
protocol is in compliance with the EFSA note released in 
July 2012, which fixes the safe daily intake of DHA+EPA 
in 2 to 4 gr per day (3.2 mg of omega-3 in mouse are 
equivalent to 2 gr in humans); VitD3: 2.5×10-5 mg/gr pro 
die is equivalent to 0.5 µg per mouse per day which is the 
higher dose described for in vivo studies (Meeker et al., 
2016); LR: 5×107 cfu/gr of LR is equivalent to 1×109 cfu 
pro die that is the dose used for in vivo studies (Zheng et 
al., 2016).
Adherent invasive Escherichia coli strain LF82
The AIEC strain LF82 (ileal Crohn’s strain, kindly provided 
by Prof. Arlette Darfeuille-Michaud, Clermont Université, 
Université d’Auvergne, Clermont-Ferrand, France) was 
cultured in MacConkey agar plates for 24 h at 37 °C and 
then sub-cultured in Luria Bertani Broth (LB; Oxoid, 
Basingstoke, UK) with overnight incubation at 150 rpm, 
37 °C.
Cell lines
Human colorectal adenocarcinoma cell lines, CACO2 and 
HT29, were obtained from the American Type Culture 
Collection (ATCC, Rockville, MA, USA). Cells were grown 
at confluence at 37 °C in Dulbecco’s minimum essential 
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functional food, which includes total of active ingredients, 
physical and chemical tests and microbiological tests.
VitD3 (Giellepi SPA), whose specific name is 25-diidrossi-
vitamin D3(1,25(OH)2D3). The manufacturer supplied a 
certificate of analysis for the use in nutritional supplements 
and functional food, which includes total of active 
ingredients, physical and purity tests.
LR (BioGaia, Stockholm, Sweden) was cultured in De 
Man, Rogosa and Sharpe (MRS; Sigma-Aldrich, Buchs, 
Switzerland) agar plates for 24 h at 37 °C and then sub-
cultured in MRS Broth with overnight incubation at 
150 rpm, 37 °C. The manufacturer supplied a certificate 
of analysis for the use in nutritional supplements and 
functional food, which includes quality control tests and 
microbiological specifications.
KLD mixture used for in vitro experiments consists of: 
KO [0.25 mg/ml] + VitD3 [100nM] + LR [1×109 cfu/ml] 
in eukaryotic cell growth media (DMEM or McCoy’s 5A); 
for in vivo experiments concentrations were: KO [0.8 mg/
gr] + VitD3 [2.5×10-5 mg/gr] + LR [5×107 cfu/gr] pro die 
in phosphate buffered saline (PBS); 0.2 ml of KLD was 
administered by gavage twice daily.
This specific ratio and combination were chosen as follows: 
KO: according to the allometric scaling laws (West and 
Brown, 2005) and since DHA+EPA are 20% in KO, by 
administering 16 mg/mouse (0.8 mg/gr) pro die, the 
protocol is in compliance with the EFSA note released in 
July 2012, which fixes the safe daily intake of DHA+EPA 
in 2 to 4 gr per day (3.2 mg of omega-3 in mouse are 
equivalent to 2 gr in humans); VitD3: 2.5×10-5 mg/gr pro 
die is equivalent to 0.5 µg per mouse per day which is the 
higher dose described for in vivo studies (Meeker et al., 
2016); LR: 5×107 cfu/gr of LR is equivalent to 1×109 cfu 
pro die that is the dose used for in vivo studies (Zheng et 
al., 2016).
Adherent invasive Escherichia coli strain LF82
The AIEC strain LF82 (ileal Crohn’s strain, kindly provided 
by Prof. Arlette Darfeuille-Michaud, Clermont Université, 
Université d’Auvergne, Clermont-Ferrand, France) was 
cultured in MacConkey agar plates for 24 h at 37 °C and 
then sub-cultured in Luria Bertani Broth (LB; Oxoid, 
Basingstoke, UK) with overnight incubation at 150 rpm, 
37 °C.
Cell lines
Human colorectal adenocarcinoma cell lines, CACO2 and 
HT29, were obtained from the American Type Culture 
Collection (ATCC, Rockville, MA, USA). Cells were grown 
at confluence at 37 °C in Dulbecco’s minimum essential 
medium (DMEM; Gibco, Life Technologies, Carlsbad, 
CA, USA) and McCoy’s 5A medium (Gibco), respectively, 
supplemented with 10% inactivated foetal calf serum (FCS; 
Euroclone, Milan, Italy) and 2 mM L-glutamine, 100 U/ml 
penicillin and 100 g/ml streptomycin (Biochrom, Berlin, 
Germany).
Confluent CACO2 or HT29 cells were grown in absence or 
presence of cytomix (tumour necrosis factor alpha (TNF-α) 
+ interferon gamma: 10 ng/ml + 250 ng/ml; Sigma) to 
induce inflammation or co-exposed to cytomix and KO, LR 
and VitD3 singularly or to cytomix and KLD for 24-48 h or 
in presence of the AIEC reference strain, LF82 (see Bacterial 
Adhesion and Invasion Assay) or LF82 and KLD, for 3 h.
Scratch test
Wound healing was assessed by the scratch test as previously 
described (Costanzo et al., 2016). Briefly, confluent HT29 
cells were seeded on to a 2 well cell-culture-slide at a density 
of 2×105 cells/ml. The linear scratch was made with a 10 
microliter sterile pipette tip and the gap widths (1 mm at 
day 0) were measured after 24 and 48 h. Cells were exposed 
to the cytomix to induce inflammation or co-exposed to 
cytomix and KLD for 24 and 48 h. Scratch wound healing 
was treated with haematoxylin and eosin staining protocol 
(H&E) and then observed under a Nikon Eclipse 80i digital 
microscope (Nikon, Tokyo, Japan) at 10× magnification.
Immunofluorescence
Cells exposed to the cytomix or co-exposed to cytomix 
and KLD or to cytomix and single components (KO, 
VitD3, LR) were grown at confluence on a microscope 
glass slide for 24 h. Then, cells were fixed for 10 min in 
PBS with 4% paraformaldehyde. Cells were washed in PBS, 
permeable by incubation for 10 min in PBS-0.1% Triton 
X-100 (Sigma), and then blocked for 30 min in PBS-1% 
BSA. For F-actin staining, samples were incubated with 
Alexa Fluor 488-conjugated Phalloidin (1:50 dilution; 
Invitrogen, Carlsbad, CA, USA) according to manufacturer’s 
instructions. 4',6-diamidino-2-phenylindole was added for 
nuclei counterstaining.
Bacterial adhesion and invasion assay
Adhesion assay
CACO2 and HT29 cells were grown on 24-well plates at 
confluence and infected with LF82 strains at a multiplicity of 
infection (MOI) of 10:1 for CACO2 and 100:1 for HT29, at 
37 °C for 3 hrs. To quantify the adherence of LF82, infected 
cells were washed twice in PBS and lysed for 10 min with 0.5 
ml of 0.1% Triton X-100 in PBS buffer. Adherent bacteria 
were recovered and plated on LB agar plates. The latter 
were incubated at 37 °C overnight and then the colonies 
were counted for statistical analysis.
Invasion assay
CACO2 and HT29 were infected and incubated as above. 
After incubation, cells were washed twice in sterile PBS 
and then incubated in DMEM and McCoy’s medium, 
respectively with 0.1 mg/ml gentamicin for 1 h to kill 
extracellular bacteria. Cells were washed twice in sterile 
PBS. Lysis, incubation and counts were performed as in 
the adhesion assay. To ensure maximum reproducibility, 
accuracy and statistical significance, adhesion and invasion 
assays were carried out simultaneously in triplicates.
Quantitative PCR analysis
Cytokine expression was detected by quantitative PCR. 
Primers were designed to non-redundant sequences 
using Primer Express v. 3.0 (Applied Biosystems, Foster 
City, CA, USA). RNA purity was assessed by 260/280 
and 260/230 nm absorbance ratio (2.0 or above). RNA 
integrity was checked by agarose-formaldehyde analysis. 
Total RNA (1 µg) was reverse- transcribed to cDNA by a 
High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems). Quantitative PCR amplification was done with 
an ABI PRISM 7300 Sequence Detection System using the 
SYBR Green kit (Applied Biosystems), according to the 
manufacturer’s instructions.
The following primers were used (Table 1). Fold of induction 
is the ratio between observed genes and endogenous control 
expression levels made in triplicate.
Trans-epithelial Electric Resistance (TEER) assay
CACO2 cells were grown at 37 °C in 5% CO2 on polyethylene 
terephthalate membrane inserts, pore size 0.4 mm 
(Falcon; Becton Dickinson, Franklin Lakes, NJ, USA) in 
DMEM supplemented with 10% FCS. TEER values were 
measured using a Millicell-ERS voltohmmeter (Millipore, 
Billerica, MA, USA) according to the manufacturer’s 
instructions. Electrodes were sterilised by immersion in 
70% ethanol, then they were washed in sterile PBS prior 
to use. Calculations for Xcm2 were made by subtracting 
values of blank inserts from all samples and multiplying 
by the area seeded with cells. Subtracting filter resistance, 
epithelial mono-layers were grown to an average TEER 
of about 700 Xcm2 tissue monolayer. Cells were infected 
with the reference AIEC strain LF82 at MOI 10:1 and 
KLD (at established concentration), applied to the apical 
transwell compartment, at 37 °C in 5% CO2. Changes in 
TEER over time were determined every 2 h and triplicate 
TEER readings from three independent experiments were 
normalised, averaged, and expressed as percent change.
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Animals
C57BL/6 female mice (8 to 9 weeks of age) were purchased 
from the animal housing unit of ENVIGO, SRL. Animals 
were housed in collective cages at 22±1 °C under a 12 h light/
dark cycle and with food and water provided ad libitum. 
Acute colitis was induced through administration of dextran 
sodium sulphate (DSS, molecular mass, 36,000-50,000 
Da; MP Biomedicals, Santa Ana, CA, USA), dissolved in 
autoclaved drinking water, for 7 days. Mice, 5 for each 
group, were randomly divided into four experimental 
groups: the control group received regular drinking water 
(UN); KLD-treated group received two daily oral gavages of 
KLD (KLD); DSS-treated group was given a solution with 
3% (w/v) DSS (DSS); fourth group received a combined 
treatment with 3% DSS and two daily oral gavages of KLD 
(DSS+KLD). Mice were daily checked for behaviour, body 
weight, stool blood and consistency.
The experimental procedures were previously approved by 
the Ministry of Health for the protection of animals used 
for experimental purposes, and the study was conducted 
in accordance with Italian regulations on animal welfare. 
The protocol was approved by the Committee on the Ethics 
of Animal Experiments of the Italian National Agency 
for New Technology, Energy and Sustainable Economic 
Development (ENEA) (Permit Number: 76/2017-PR).
Assessment of DSS-induced colitis and histological 
score
All animals were daily examined and the clinical score 
(CS) was assessed according to the criteria of Maxwell et 
al. (Maxwell et al., 2009) by assessing stool consistency 
(0 for normal stool, 1 for moist/sticky stool, 2 for soft stool, 
3 for diarrhoea), presence of blood in stool (0 for no blood, 
1 for evidence of blood in stool or around anus, and 2 for 
severe bleeding) and general appearance of the animal 
(0 was assigned if normal, 1 for ruffled fur or altered gait, 
2 for lethargic or moribund). Mice were daily weighed, and 
the percentage of weight loss was calculated in relation to 
the starting weight using the formula: [(Weight on day X – 
Initial weight) / Initial weight] × 100 (Maxwell et al., 2009).
The 7th day, animals were euthanised, colons removed 
and examined for weight, length (measured from the anus 
to the top of the caecum) and stool consistency. Distal 
colonic specimens were frozen in liquid nitrogen or fixed 
immediately in a 10% (w/v) formalin solution for further 
analyses.
For histological analysis, fixed colonic tissues were 
embedded in paraffin, sectioned (4 µm thickness), mounted 
on glass slides, and deparaffinised. Slices were stained 
using standard haematoxylin and eosin (H&E) techniques. 
Samples were analysed by light microscopy and were scored 
according to previous procedure. (Maxwell et al., 2009) (0 
for normal; 1 for slight increase in cellularity (primarily 
lymphocytes in the lamina propria); 2 for increase in 
cellularity, neutrophils present, mild oedema; 3 for diffuse 
increase in cellularity, focal erosions or ulcerations of 
mucosa; 4 increased cellularity, large and or multifocal 
mucosal ulcerations; 5 for diffuse ulceration, loss of mucosal 
architecture). Experiments were double-blind.
Immunohistochemistry
Sections (4 mm) of paraffin-embedded intestinal colonic 
samples from mice were prepared following the standard 
protocol. Briefly, sections were dewaxed for 20 min at 
56 °C and incubated in ab973 buffer pH 6.0 for 20 min at 
95 °C. Afterward, sections were washed in water for 30 min 
and peroxidases inhibited by incubation in 3% H2O2 for 
15 min. Sections were treated with Rodent Block for 50 min 
and incubated with primary anti-VDR (D-6) antibody 
(SantaCruz Biotechnologies, Dallas, TX, USA), diluted 
1:50 in phosphate-buffered saline over night at 4 °C in a 
moist chamber. Then, they were washed in TBS-T 0.1%, 
incubated for 15 min with Mouse on Mouse HRP Polymer 
(ab127055 – Mouse on Mouse Polymer IHC Kit; Abcam, 
Cambridge, UK), and washed again TBS-T 0.1%. The DAB 
detection kit (DAKO; Abcam) was used, as suggested by 
the providers, to visualise the antigen. Finally, samples were 
stained with H&E.
Table 1. Primer sequences used for quantitative PCR.
Gene1 F/R2 Primer 
TNF-α F 5’-TCTGGCCCAGGCAGTCAGATC-3’
R 5’-CAGTGATGTTGGGGATAAAGAGC-3’
IL-8 F 5’-ATGACTTCCAAGCTGGCCGTGGCT-3’
R 5’-TCTCAGCCCTCTTCAAAAACTTCTC-3’
IL-1β F 5’-CGAGGCAGTATCACTCATTG-3’ 
R 5-CGTTGCTTGGTTCTCCTTGT-3’
IL-6 F 5’-CAAGTCGGAGGCTTAATTACACATG-3’
R 5’-AGAAAAGAGTTGTGCAATGGCA-3’
IL-10 F 5’-AACAAAGGACCAGCTGGACAAC-3’
R 5’-GGCAACCCAAGTAACCCTTAAA-3’
VDR (cells) F 5’-GGACTGCCGCATCACCAA-3’
R 5’-TCATCTCCCGCTTCCTCT-3’
VDR (mice) F 5’-CACCTGCCCCTTCAATGG-3’
R 5’-GCAGTGTCGCCGGTTGTC-3’
GAPDH (cells 
and mice)
F 5’-AACTTTGGCATTGTGGAAGG-3’
R 5’-CACATTGGGGGTAGGAACAC-3’
1 TNF-α = tumour necrosis factor alpha; IL = interleukin; VDR = vitamin 
D receptor; GAPDH = glyceraldehyde 3-phosphate dehydrogenase 
(household gene).
2 F = forward; R = reverse.
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Statistics
Data are given as mean ± standard deviation. All 
experiments in vitro were repeated three times. Comparison 
between groups was performed by a two-tailed Student 
t-test (significance taken as P<0.05). In vivo experiments 
are the mean of five observations per group. Comparison 
between groups was performed by non-parametric test 
(Mann-Whitney) (values of P<0.05 were considered 
significant).
3. Results
KLD restores epithelial cell-cell adhesion and tissue 
architecture altered by cytomix-induced inflammation
F-actin localisation and expression were determined by 
immunofluorescence in CACO2 cells. F-actin filaments, 
components of the actin cytoskeleton that in eukaryotes 
are essential to junctional assembly, are organised into 
stress fibres (SFs) that are known to increase in number 
and thickness during inflammation. Results showed that 
exposure to cytomix caused a sharp increase in SFs numbers 
with a disorganisation in junctional assembly in all samples 
compared to untreated cells. However, KLD promoted a 
proper tissue re-organisation strongly reducing SFs, better 
than single components (Figure 1).
It is worth noting that LR, despite having a well-known 
role in preventing and/or treating gastrointestinal diseases 
(Cruchet et al., 2015), minimally alters the morphology of 
intestinal barrier (Figure 1), albeit much less than other 
commensal species, like the AIEC reference strain LF82 
(Supplementary Figure S1A). Nevertheless, the combination 
of LR with VitD3 and KO (KLD) completely abolished this 
effect. Interestingly, KLD did not change the vitality of LR in 
both cell lines (CACO2, HT29) after 24 h (Supplementary 
Figure S1B).
KLD strongly inhibits adhesiveness and invasiveness of 
AIEC bacteria
KLD significantly decreased adhesion as well as invasion 
of LF82 in CACO2 and HT29 cells (P<0.01 or P<0.05, 
respectively) (Figure 2A). Accordingly, KLD significantly 
improved cell morphology of the epithelial barrier by 
decreasing SFs (Figure 2B) and increasing the TEER (Figure 
2C), both deeply altered by LF82 exposure. LR was found 
to be more effective in reducing adhesiveness as well as 
invasiveness of AIEC bacteria when administered in KLD 
formulation (reduction of around 75 and 64%, respectively) 
(Figure 2A) than alone (reduction of around 50% and 40%, 
respectively) (Supplementary Figure S2).
KLD decreases mRNA levels of IL-8 and TNF-α and 
increases mRNA expression of VDR during inflammation
KLD significantly reduced IL-8 and TNF-α mRNA 
levels in CACO2 and HT29 cells (P<0.01) as much as 
KO and VitD3 alone, however, it was able to strengthen 
the anti-inflammatory potential of LR as compared to 
LR administered alone (Figure 3). Additionally, KLD 
significantly increased the expression level of vitamin D 
receptor (VDR) (P<0.01) (Figure 3).
KLD significantly improves mucosal healing during 
cytomix-induced inflammation
Scratched cells exposed to cytomix showed a delay of 
~9% and ~26% of wound healing (WH) as compared to 
unexposed cells (24 h: 59.39±11.82 vs 68.32±9.32%, P<0.01; 
48 h: 35.41±8.72 vs 61.49±7.45%, P<0.001). However, co-
treatment with KLD significantly improved the rate of WH 
when compared to cytomix at 24 (+15%) and 48 h (+33%) 
(68.32±9.32 vs 52.81±8.23%, P<0.01 and 61.49±7.45 vs 
27.95±7.81%, P<0.01, respectively) (Figure 4, Supplementary 
Figure S3).
KLD significantly reduces the severity of DSS-induced 
colitis in mice
After DSS treatment of mice and induction of severe colitis, 
results showed that animals treated with DSS+KLD had a 
statistically significant recovery of body weight (P<0.01), CS 
(P<0.01), and colon length (P<0.01), as compared to DSS-
treated animals (Figure 5A, B and C). Anti-inflammatory 
effects of KLD were further confirmed by the histological 
analysis which showed an important recovery of the 
morphological features of the intestinal mucosa and a 
significant reduction of the histological score (P<0.05) 
(Figure 5D and E).
Figure 1. Cytomix induces stress fibres (SFs), but KLD reduces 
SFs formation better than single components. UN = untreated; 
KO = krill oil; LR = Lactobacillus reuteri; VitD3 = vitamin D3; 
KLD = KO + LR + VitD3; CYT = cytomix (TNF-α + IFN-γ).
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Figure 2. (A) Effects of KLD on adhesion and invasion of adherent invasive Escherichia coli strain LF82. (B) Effect of KLD on 
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Moreover, tissue samples taken from the large colon of 
mice were analysed to assess the mRNA expression of 
the pro-inflammatory cytokines, TNFα, IL-1β and IL-
6, the anti-inflammatory cytokine IL-10 and the VDR. 
Results showed a dramatic decrease of TNFα, IL-1β, IL-6 
(P<0.001) as well as a strong increase of IL-10 and VDR 
(P<0.001 and P<0.01, respectively) in mice treated with 
DSS+KLD as compared to mice treated with DSS (Figure 6). 
To confirm the triggering of vitamin D signalling, the VDR 
expression was also confirmed by immunohistochemistry. 
Results showed that VDR levels were severely reduced after 
DSS treatment, while exposure to KLD restored a proper 
condition (Figure 7).
4. Discussion
Much evidence supports the view that the lack of gut 
barrier integrity is strongly associated to gastrointestinal 
as well as extra-intestinal diseases (König et al., 2016; Mittal 
and Coopersmith, 2014; Odenwald and Turner, 2017). 
Thus, targeting and restoring the epithelial barrier is a 
tempting therapeutic goal and agents usable in this sense 
are presently highly desirable. This is especially true for 
intestinal chronic inflammatory entities, like IBD, that 
are becoming an emergency in developed and developing 
countries (Ye et al., 2015).
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IBD is characterised by defects in the intestinal epithelial 
barrier as well as imbalance of the intestinal microbiota, 
resulting in active inflammation. These diseases are usually 
managed with immunomodulators, corticosteroids or, more 
recently, biological agents that, next to their therapeutic 
action, have important side effects of toxic nature, often 
harmful to the health of patients. Hence, current research 
into original therapies to treat intestinal inflammation is 
focusing on no-drug therapies.
Studies to date reveal that vitamin D signalling has 
widespread effects on gut homeostasis, (Dimitrov and 
White, 2017). Vitamin D elicits its effects through binding 
to the VDR, a transcription factor for genes with promoters 
containing vitamin D response elements (VDREs). 
Strategies to restore VDR expression in inflamed mucosa 
may be important for preventing and treating IBD and other 
illness (Shang and Sun, 2017; Wu et al., 2010, 2015). As well, 
relevant data are deriving from studies on probiotics as 
selective modulators of intestinal microbiota. In particular, 
remodelling microbiota with LR reduced inflammation 
in animal models and humans (He et al., 2017; Oliva et 
al., 2012; Thomas et al., 2016). In our study, we observed 
that LR itself may produce a mild increase in mucosal 
inflammation, as shown by the increase in SFs number 
and pro-inflammatory cytokine expression. This event, also 
reported by other authors (Liu et al., 2010; Mangalat et al., 
2012), is attributable to the fact that LR is still a bacterium 
and, as such, somehow stimulates the immune system, 
although much less than other more harmful commensal 
species, like the AIEC bacteria (as also shown by our data). 
The combination with KO and VitD3 abrogates this effect, 
while maintaining unaltered the properties of the probiotic. 
Indeed, our results show that, within KLD, LR shows the 
same vitality as when it is grown in standard medium and, 
more interestingly, it is even more competitive with AIEC 
bacteria. This is extremely relevant since in different chronic 
inflammatory conditions, including IBD, AIEC strains 
are significantly increased and the use of probiotics may 
represent in the future a successful strategy to reduce their 
number and pathogenicity, as already suggested (Huebner 
et al., 2011).
Recent studies show the positive effects of omega-3 PUFA 
for the treatment of intestinal inflammation as they alleviate 
the symptoms and promote better mucosal integrity. 
Furthermore, some evidence show that omega-3 fatty acids 
can reduce body weight gain and chronic inflammation 
through modulation of the gut microbiota (Kaliannan et 
al., 2016; Tabbaa et al., 2013).
Hence, it was born the idea to combine the KO, that is 
rich in n-3 PUFAs, with VitD3, both deficient in patients 
with chronic intestinal inflammation, and LR, studying 
its potential to reduce intestinal inflammation by using a 
wide range of investigations. Indeed, we explored cell-cell 
adhesion and morphology of epithelial cells, both related 
to epithelial permeability and analysed the expression 
levels of pro-inflammatory cytokines, whose increase is 
strictly linked to inflammation. Moreover, we observed 
the resistance of the epithelial layer to the infectiveness 
of detrimental bacteria, typically increased during 
inflammation. Interestingly, our results show that KLD 
has significant effects on the intestinal mucosa, strongly 
decreasing inflammation, improving epithelial restitution 
and permeability, also strengthening vitamin D activity by 
enhancing VDR expression, as well as reducing harmfulness 
of some types of commensal bacteria.
We believe that this outcome is due to the fact that KLD 
is active on two fronts: on the one hand, it reduces the 
epithelial damage by improving barrier integrity and 
mucosal healing; on the other hand, it contributes to 
restore a condition of intestinal eubiosis by limiting the 
effectiveness of groups of pathobionts that increase during 
inflammation. Concurrently, KLD clearly lessens the 
aforementioned immunomodulatory effect caused by LR 
without modifying its beneficial properties. Interestingly, 
LR contrasts more effectively AIEC harmfulness when 
administered in KLD formulation than when administered 
alone.
In order to assess the effects of KLD in a multicellular 
system, more complex than established cell lines and closer 
to human model, we turned to the mouse model. While 
several studies addressed the question whether the use 
of omega-3 or vitamin D or probiotics could be helpful 
to ameliorate colitis in humans and/or animal models 
(Barbalho et al., 2016; Claes et al., 2011; Ganji-Arjenaki and 
Rafieian-Kopaei, 2017; Hlavaty et al., 2015; Schwanke et al., 
2016; Uranga et al., 2016), this is the first time that they have 
been administered together to assess anti-inflammatory 
effects in the gut. Accordingly, we administered KLD to 
C57BL/6 mice with a DSS-induced colitis. We found that 
treatment with KLD causes a remarkable reduction of 
acute colitis, in terms of recovery of body weight, clinical 
and histological scores and large intestine length. Besides, 
levels of proinflammatory cytokines, TNF-α, IL-1β and 
IL-6, were significantly down-regulated in the inflamed 
tissues of KLD+DSS-treated mice as compared to DSS-
treated mice, while the anti-inflammatory cytokine IL-10 
and VDR were significantly increased. Furthermore, given 
the importance of appropriate functioning of vitamin D and 
since VDR also functions as a transcription factor, we also 
used immunohistochemistry and found that VDR levels 
were strongly improved after KLD treatments in murine 
inflamed colon, suggesting its proper activation.
In conclusion, in vivo results confirm that KLD strongly 
reduces gut inflammation. All the results obtained from 
the study suggest that KLD would allow the patient 
with intestinal chronic inflammation to benefit from 
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therapeutic coverage, even for very protracted periods, 
with no side effects. Certainly in vitro and in vivo models 
are not exhaustive and need further investigation in clinical 
trials. However if the results on man will confirm this data, 
this would open the horizon to a wider diffusion of this 
non-pharmacological treatment in patients with other 
immunological and also tumoural illnesses. Indeed, there 
are now a number of medical fields in which the correlation 
between immune regulatory activity, disease activity and 
prognosis has been demonstrated.
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Figure S1. (A) Effects of Lactobacillus reuteri (LR) and 
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